Carisbamate
![]() |
|
Systematic (IUPAC) name | |
---|---|
(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol
|
|
Identifiers | |
CAS Number | 194085-75-1 ![]() |
ATC code | N03AX19 (WHO) |
PubChem | CID: 9942577 |
ChemSpider | 8118189 ![]() |
UNII | P7725I9V3Z ![]() |
ChEMBL | CHEMBL2087003 ![]() |
Chemical data | |
Formula | C9H10ClNO3 |
Molecular mass | 215.633 g/mol |
|
|
|
|
![]() ![]() |
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.[1][2]
On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate.[3] Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.
A double-blind, placebo-controlled trial cf carisbamate in 323 patients with migraine failed to demonstrate that the active drug was more effective than placebo.[4] However, carisbamate was well tolerated at doses up to 600 mg/day.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Anticonvulsants
- Carbamates
- Alcohols
- Chloroarenes
- Johnson & Johnson
- GABAA receptor positive allosteric modulators
- Anticonvulsant stubs